Dynamic conditioning of porcine kidney grafts with extracellular vesicles derived from urine progenitor cells: A proof-of-concept study

Abstract

	•UPCs from porcine urine can be used to generate a cell therapy product based on extracellular vesicles (pUPC-EVs).
	•pUPC-EVs injection during HMP and NMP decreases cell damage markers and has an immunomodulatory effect.
	•pUPC-EVs-treated kidneys have distinct biochemical, metabolic, and transcriptomic profiles highlighting targets of interest.
	•Our results pave the way for combining machine perfusion with EV-based cell therapy for kidney conditioning.

Keywords

cell therapy / exosomes / extracellular vesicles / kidney preservation / kidney transplantation / machine perfusion / preclinical porcine model / urine progenitor/stem cells

References

[1] Nieuwenhuijs-MoekeGJ, Pischke SE, BergerSP, et al. Ischemia and reperfusion injury in kidney transplantation: relevant mechanisms in injury and repair. J Clin Med. 2020; 9(1): 253.

[2] MoersC, Pirenne J, PaulA, PloegRJ. Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med. 2012; 366(8): 770-771.

[3] HoogduijnMJ, Montserrat N, van der LaanLJW, et al. The emergence of regenerative medicine in organ transplantation: 1st European Cell Therapy and Organ Regeneration Section meeting. Transpl Int Off J Eur Soc Organ Transplant. 2020; 33(8): 833-840.

[4] ErpicumP, Weekers L, DetryO, et al. Infusion of third-party mesenchymal stromal cells after kidney transplantation: a phase I-II, open-label, clinical study. Kidney Int. 2019; 95(3): 693-707.

[5] SaidiRF, Moghadasali R, ShekarchianS. Utilization of mesenchymal stem cells in kidney transplantation: from bench to bedside. Iran J Kidney Dis. 2019; 13(4): 213-224.

[6] VandermeulenM, Erpicum P, WeekersL, et al. Mesenchymal stromal cells in solid organ transplantation. Transplantation. 2020; 104(5): 923-936.

[7] BaulierE, Favreau F, Le CorfA, et al. Amniotic fluid-derived mesenchymal stem cells prevent fibrosis and preserve renal function in a preclinical porcine model of kidney transplantation. Stem Cells Transl Med. 2014; 3(7): 809-820.

[8] SteichenC, Erpicum P. Combining cell-based therapy and normothermic machine perfusion for kidney graft conditioning has gone one step further. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 2021; 21(4): 1359-1360.

[9] BelliniMI, Tortorici F, AmabileMI, D’Andrea V. Assessing kidney graft viability and its cells metabolism during machine perfusion. Int J Mol Sci. 2021; 22(3): 1121.

[10] HosgoodSA, HoffM, NicholsonML. Treatment of transplant kidneys during machine perfusion. Transpl Int Off J Eur Soc Organ Transplant. 2021; 34(2): 224-232.

[11] ThompsonER, BatesL, IbrahimIK, et al. Novel delivery of cellular therapy to reduce ischemia reperfusion injury in kidney transplantation. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 2021; 21(4): 1402-1414.

[12] ChatauretN, BadetL, BarrouB, Hauet T. Ischemia-reperfusion: from cell biology to acute kidney injury. Prog En Urol J Assoc Fr Urol Société Fr Urol. 2014; 24(1): S4-12.

[13] GregoriniM, Corradetti V, PattonieriEF, et al. Perfusion of isolated rat kidney with mesenchymal stromal cells/extracellular vesicles prevents ischaemic injury. J Cell Mol Med. 2017; 21(12): 3381-3393.

[14] NicholsonML, Hosgood SA. Renal transplantation after ex vivo normothermic perfusion: the first clinical study. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 2013; 13(5): 1246-1252.

[15] HosgoodSA, Nicholson ML. Ex vivo normothermic perfusion of declined human kidneys after inadequate in situ perfusion. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 2014; 14(2): 490-491.

[16] SteichenC, GiraudS, BonD, et al. Barriers and advances in kidney preservation. BioMed Res Int. 2018; 2018: 9206257.

[17] von HornC, MinorT. Improved approach for normothermic machine perfusion of cold stored kidney grafts. Am J Transl Res. 2018; 10(6): 1921-1929.

[18] BogenspergerC, Hofmann J, MessnerF, et al. Ex vivo mesenchymal stem cell therapy to regenerate machine perfused organs. Int J Mol Sci. 2021; 22(10): 5233.

[19] Sierra-ParragaJM, Munk A, AndersenC, et al. Mesenchymal stromal cells are retained in the porcine renal cortex independently of their metabolic state after renal intra-arterial infusion. Stem Cells Dev. 2019; 28(18): 1224-1235.

[20] PoolM, Eertman T, Sierra ParragaJ, et al. Infusing mesenchymal stromal cells into porcine kidneys during normothermic machine perfusion: intact MSCs can be traced and localised to glomeruli. Int J Mol Sci. 2019; 20(14): E3607.

[21] BrasileL, HenryN, OrlandoG, Stubenitsky B. Potentiating renal regeneration using mesenchymal stem cells. Transplantation. 2019; 103(2): 307-313.

[22] LohmannS, PoolMBF, RozenbergKM, et al. Mesenchymal stromal cell treatment of donor kidneys during ex vivo normothermic machine perfusion: a porcine renal autotransplantation study. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 2021; 21(7): 2348-2359.

[23] KimDK, KangB, KimOY, et al. EVpedia: an integrated database of high-throughput data for systemic analyses of extracellular vesicles. J Extracell Vesicles. 2013; 2(1): 20384.

[24] KeshtkarS, Azarpira N, GhahremaniMH. Mesenchymal stem cell-derived extracellular vesicles: novel frontiers in regenerative medicine. Stem Cell Res Ther. 2018; 9(1): 63.

[25] EirinA, LermanLO. Mesenchymal stem/stromal cell–derived extracellular vesicles for chronic kidney disease: are we there yet?. Hypertension. 2021; 78(2): 261-269.

[26] JiangZZ, LiuYM, NiuX, et al. Exosomes secreted by human urine-derived stem cells could prevent kidney complications from type I diabetes in rats. Stem Cell Res Ther. 2016; 7(1): 24.

[27] RatajczakMZ, Ratajczak J. Extracellular microvesicles/exosomes: discovery, disbelief, acceptance, and the future?. Leukemia. 2020; 34(12): 3126-3135.

[28] GrangeC, Bellucci L, BussolatiB, RanghinoA. Potential applications of extracellular vesicles in solid organ transplantation. Cells. 2020; 9(2): E369.

[29] LazanaI, Vassilopoulos G. A “waste product” to save the day in the field of transplantation: the evolving potential of extracellular vesicles. Immunology. 2022.

[30] BharadwajS, LiuG, ShiY, et al. Multipotential differentiation of human urine-derived stem cells: potential for therapeutic applications in urology. Stem Cells Dayt Ohio. 2013; 31(9): 1840-1856.

[31] SteichenC, Si-Tayeb K, WulkanF, et al. human induced pluripotent stem (hiPS) cells from urine samples: a non-integrative and feeder-free reprogramming strategy. Curr Protoc Hum Genet. 2017; 92: 21.7.1-21.7.22.

[32] BurdeyronP, GiraudS, HauetT, Steichen C. Urine-derived stem/progenitor cells: a focus on their characterization and potential. World J Stem Cells. 2020; 12(10): 1080-1096.

[33] SchossererM, Reynoso R, WallyV, et al. Urine is a novel source of autologous mesenchymal stem cells for patients with epidermolysis bullosa. BMC Res Notes. 2015; 8(1).

[34] LiuG, WuR, YangB, et al. Human urine-derived stem cell differentiation to endothelial cells with barrier function and nitric oxide production. Stem Cells Transl Med. 2018; 7(9): 686-698.

[35] LazzeriE, Ronconi E, AngelottiML, et al. human urine-derived renal progenitors for personalized modeling of genetic kidney disorders. J Am Soc Nephrol JASN. 2015; 26(8): 1961-1974.

[36] ArcolinoFO, Hosgood S, AkalayS, et al. De novo SIX2 activation in human kidneys treated with neonatal kidney stem/progenitor cells. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 2022; 22(12): 2791-2803.

[37] LepoittevinM, Blancart-Remaury Q, KerforneT, PellerinL, HauetT, ThuillierR. Comparison between 5 extractions methods in either plasma or serum to determine the optimal extraction and matrix combination for human metabolomics. Cell Mol Biol Lett. 2023; 28(1): 43.

[38] MaunsbachAB, Marples D, ChinE, et al. Aquaporin-1 water channel expression in human kidney. J Am Soc Nephrol JASN. 1997; 8(1): 1-14.

[39] Ticozzi-ValerioD, Raimondo F, PittoM, et al. Differential expression of AQP1 in microdomain-enriched membranes of renal cell carcinoma. Proteomics Clin Appl. 2007; 1(6): 588-597.

[40] JordanNP, TingleSJ, ShuttleworthVG, et al. MiR-126-3p is dynamically regulated in endothelial-to-mesenchymal transition during fibrosis. Int J Mol Sci. 2021; 22(16): 8629.

[41] CurciC, Castellano G, StasiA, et al. Endothelial-to-mesenchymal transition and renal fibrosis in ischaemia/reperfusion injury are mediated by complement anaphylatoxins and Akt pathway. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc—Eur Ren Assoc. 2014; 29(4): 799-808.

[42] LuM, WangP, ZhouS, et al. Ecdysone elicits chronic renal impairment via mineralocorticoid-like pathogenic activities. Cell Physiol Biochem. 2018; 49(4): 1633-1645.

[43] LuM, WangP, GeY, et al. Activation of mineralocorticoid receptor by ecdysone, an adaptogenic and anabolic ecdysteroid, promotes glomerular injury and proteinuria involving overactive GSK3β pathway signaling. Sci Rep. 2018; 8(1): 12225.

[44] MoriT, OhsakiY, Oba-YabanaI, Ito S. Diuretic usage for protection against end-organ damage in liver cirrhosis and heart failure: diuretic usage in volume overload diseases. Hepatol Res. 2017; 47(1): 11-22.

[45] AggarwalS, Randhawa PK, SinghN, JaggiAS. Role of ATP-sensitive potassium channels in remote ischemic preconditioning induced tissue protection. J Cardiovasc Pharmacol Ther. 2017; 22(5): 467-475.

[46] SpeesJL, LeeRH, GregoryCA. Mechanisms of mesenchymal stem/stromal cell function. Stem Cell Res Ther. 2016; 7(1): 125.

[47] Aghajani NargesiA, Lerman LO, EirinA. Mesenchymal stem cell-derived extracellular vesicles for kidney repair: current status and looming challenges. Stem Cell Res Ther. 2017; 8(1): 273.

[48] AkyurekliC, LeY, RichardsonRB, FergussonD, TayJ, AllanDS. A systematic review of preclinical studies on the therapeutic potential of mesenchymal stromal cell-derived microvesicles. Stem Cell Rev Rep. 2015; 11(1): 150-160.

[49] AlbertiG, RussoE, CorraoS, et al. Current perspectives on adult mesenchymal stromal cell-derived extracellular vesicles: biological features and clinical indications. Biomedicines. 2022; 10(11): 2822.

[50] HiltbrunnerS, Larssen P, EldhM, et al. Exosomal cancer immunotherapy is independent of MHC molecules on exosomes. Oncotarget. 2016; 7(25): 38707-38717.

[51] MunkA, DuvaldCS, PedersenM, et al. Dosing limitation for intra-renal arterial infusion of mesenchymal stromal cells. Int J Mol Sci. 2022; 23(15): 8268.

[52] EirinA, ZhuXY, PuranikAS, et al. Mesenchymal stem cell-derived extracellular vesicles attenuate kidney inflammation. Kidney Int. 2017; 92(1): 114-124.

[53] TimsitMO, García-Cardeña G. Flow-dependent endothelial function and kidney dysfunction. Semin Nephrol. 2012; 32(2): 185-191.

[54] GiraudS, Favreau F, ChatauretN, ThuillierR, MaigaS, HauetT. Contribution of large pig for renal ischemia-reperfusion and transplantation studies: the preclinical model. J Biomed Biotechnol. 2011; 2011: 532127.

[55] AnandRP, LayerJV, HejaD, et al. Design and testing of a humanized porcine donor for xenotransplantation. Nature. 2023; 622(7982): 393-401.

[56] LoupyA, Goutaudier V, GiarraputoA, et al. Immune response after pig-to-human kidney xenotransplantation: a multimodal phenotyping study. Lancet Lond Engl. 2023; 402(10408): 1158-1169.

[57] KozlovM. Monkey survives for two years after gene-edited pig-kidney transplant. Nature. 2023; 622(7983): 437-438.

[58] KaminskiJ, Delpech PO, Kaaki-HosniS, PromeyratX, HauetT, HannaertP. Oxygen consumption by warm ischemia-injured porcine kidneys in hypothermic static and machine preservation. J Surg Res. 2019; 242: 78-86.

[59] PoolMBF, VosJ, EijkenM, et al. Treating ischemically damaged porcine kidneys with human bone marrow-and adipose tissue-derived mesenchymal stromal cells during ex vivo normothermic machine perfusion. Stem Cells Dev. 2020; 29(20): 1320-1330.

[60] HosgoodSA, BarlowAD, YatesPJ, Snoeijs MGJ, van HeurnELW, NicholsonML. A pilot study assessing the feasibility of a short period of normothermic preservation in an experimental model of non heart beating donor kidneys. J Surg Res. 2011; 171(1): 283-290.

[61] FoguenneM, MacMillan S, KronP, et al. Current evidence and future perspectives to implement continuous and end-ischemic use of normothermic and oxygenated hypothermic machine perfusion in clinical practice. J Clin Med. 2023; 12(9): 3207.

[62] RijkseE, BouariS, KimenaiHJAN, et al. Additional normothermic machine perfusion versus hypothermic machine perfusion in suboptimal donor kidney transplantation: protocol of a randomized, controlled, open-label trial. Int J Surg Protoc. 2021; 25(1): 227-237.

[63] GiraudS, Kerforne T, ZelyJ, et al. The inhibition of eIF5A hypusination by GC7, a preconditioning protocol to prevent brain death-induced renal injuries in a preclinical porcine kidney transplantation model. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 2020; 20(12): 3326-3340.

[64] TilletS, GiraudS, KerforneT, et al. Inhibition of coagulation proteases Xa and IIa decreases ischemia–reperfusion injuries in a preclinical renal transplantation model. Transl Res. 2016; 178: 95-106.

[65] JochmansI, LerutE, van PeltJ, Monbaliu D, PirenneJ. Circulating AST, H-FABP, and NGAL are early and accurate biomarkers of graft injury and dysfunction in a preclinical model of kidney transplantation. Ann Surg. 2011; 254(5): 784-792.

[66] WuH, CraftML, WangP, et al. IL-18 contributes to renal damage after ischemia-reperfusion. J Am Soc Nephrol. 2008; 19(12): 2331-2341.

[67] ShibaharaS. Regulation of heme oxygenase gene expression. Semin Hematol. 1988; 25(4): 370-376.

[68] HaDH, keunKimH, LeeJ, et al. Mesenchymal stem/stromal cell-derived exosomes for immunomodulatory therapeutics and skin regeneration. Cells. 2020; 9(5): 1157.

[69] ZhouD, FuH, LiuS, et al. Early activation of fibroblasts is required for kidney repair and regeneration after injury. FASEB J Off Publ Fed Am Soc Exp Biol. 2019; 33(11): 12576-12587.

[70] VerstraetenL, Den Abt R, GhesquièreB, JochmansI. Current insights into the metabolome during hypothermic kidney perfusion-a scoping review. J Clin Med. 2023; 12(11): 3613.

[71] MulveyJF, Shaheed SU, CharlesPD, et al. Perfusate proteomes provide biological insight into oxygenated versus standard hypothermic machine perfusion in kidney transplantation. Ann Surg. 2023; 278(5): 676-682.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.